2006
DOI: 10.1016/j.transproceed.2006.10.040
|View full text |Cite
|
Sign up to set email alerts
|

A Cyclosporine-Based Immunosuppressive Regimen May Be Better Than Tacrolimus for Long-Term Liver Allograft Survival in Recipients Transplanted for Hepatitis C

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0

Year Published

2007
2007
2013
2013

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 23 publications
(13 citation statements)
references
References 8 publications
0
13
0
Order By: Relevance
“…25 Studies that have demonstrated a beneficial effect of CsA on HCV have only been able to do so in genotype 1, generally in conjunction with interferon. [26][27][28][29][30] We used a forward genetics approach to investigate the mechanism of CsA inhibition of the HCV replicon. CsA selected for mutations in NS5A and NS5B.…”
Section: Discussionmentioning
confidence: 99%
“…25 Studies that have demonstrated a beneficial effect of CsA on HCV have only been able to do so in genotype 1, generally in conjunction with interferon. [26][27][28][29][30] We used a forward genetics approach to investigate the mechanism of CsA inhibition of the HCV replicon. CsA selected for mutations in NS5A and NS5B.…”
Section: Discussionmentioning
confidence: 99%
“…Direct comparison of patients who received either CsA or Tacrolimus (FK506), the latter of which did not have any anti-HCV effect in vitro , failed to show significant difference in the severity of recurrent HCV in most studies [118,119,120,121]. On the other hand, combination of IFN-a and CsA was more effective in achieving sustained virologic response than IFN-a monotherapy, especially in patients with genotype 1 virus, high viral load, or both [122,123].…”
Section: Cyclophilins and Hcvmentioning
confidence: 99%
“…The 3-year actuarial risk of fibrosis stage 3 or 4 for CsA was 46% and for TAC 80%, showing an increased risk of histological recurrence in patients on TAC compared to those on CsA. Other groups have shown higher graft survival and lower incidence of fibrosing cholestatic hepatitis in LT recipients on CsA-based immunosuppression [17]. However, several conflicting reports have also been published regarding the efficacy of CsA in the LT population; therefore, significant uncertainty regarding the potential role of CsA in the HCV transplant recipient remains [18][19][20][21].…”
Section: Introductionmentioning
confidence: 99%